FDA Approves First Dual-Vector Gene Therapy For OTOF-Related Congenital Deafness
The FDA on April 23, 2026 approved the first dual-vector gene therapy for congenital deafness caused by OTOF mutations, authorizing Otarmeni (lunsotogene parvec-cwha) for pediatric and adult patients.[1]
The treatment uses two adeno-associated viral vectors to deliver a working OTOF gene directly into the cochlea in a one-time, bilateral surgical procedure via needle and microcatheter. The approval covers patients with severe to profound hearing loss tied to the OTOF gene who have preserved outer hair cell function and no prior cochlear implant in the treated ear. Common side effects listed include middle ear infection, nausea, dizziness and procedural pain, and the FDA characterized the decision as "groundbreaking" under its National Priority Voucher pilot program.[1]
The episode traces back to the 1999 discovery that OTOF mutations cause DFNB9, a nonsyndromic congenital deafness that disrupts otoferlin and synaptic transmission in inner ear hair cells. Decibel Therapeutics formed in 2015 and partnered with Regeneron in 2017 to develop a dual-AAV candidate called DB-OTO; Regeneron later acquired Decibel and moved the program forward, securing an investigational new drug clearance in October 2022 and launching the CHORD phase 1/2 trial in September 2023. Early pediatric results in 2024 showed large hearing gains, and broader 2025 data on safety and efficacy set the stage for today's approval.[2]
Regeneron says it will provide Otarmeni at no cost to eligible patients in the United States, and the FDA will hold a public meeting on June 4 to discuss program implementation, eligibility and distribution. Advocates and scientists hailed the approval on social media as a major breakthrough that targets the genetic cause of this rare deafness, with trial reports showing many patients regained near-normal hearing.[1]
The approval of Otarmeni is seen as a significant milestone in the field of gene therapy, particularly for rare genetic disorders. Approximately 200,000 individuals worldwide suffer from OTOF-related deafness, highlighting the urgent need for effective treatments. The fact that Regeneron will provide this therapy at no cost to eligible patients in the U.S. addresses a critical barrier often faced with advanced therapies that can be prohibitively expensive. Social media users, including @Pharmacy_Times and @CRISPRKING, have praised this development as a groundbreaking achievement, emphasizing its potential to restore hearing to levels previously considered unattainable.
However, while the excitement is palpable, there are still discussions about the broader implications of this approval. Some experts caution that while Otarmeni represents a leap forward, it also raises questions about long-term efficacy and safety, as well as the sustainability of providing such therapies at no cost. As @UCSF_OHNS points out, this advancement is just one step in the ongoing journey of hearing research, indicating that further studies will be needed to fully understand its impact on patients' lives and the healthcare system at large.
Show source details & analysis (2 sources)
📊 Relevant Data
Approximately 200,000 people worldwide are deaf due to mutations in the OTOF gene.
Experimental Gene Therapy Enables Hearing in Five Children Born Deaf — Harvard Medical School
In the United States, about 2 to 3 out of every 1,000 children are born with a detectable level of hearing loss in one or both ears.
Quick Statistics About Hearing, Balance, & Dizziness — National Institute on Deafness and Other Communication Disorders (NIDCD)
The manufacturer, Regeneron, is providing the gene therapy Otarmeni at no cost to eligible patients in the United States.
FDA approves first gene therapy for genetic hearing loss — NBC News
📌 Key Facts
- The FDA approved Otarmeni (lunsotogene parvec-cwha), identified as the first dual adeno-associated virus (AAV) vector–based gene therapy for hearing loss.
- The FDA characterized the approval as "groundbreaking" and said the therapy is the sixth drug—and the first gene therapy—approved under the National Priority Voucher (CNPV) pilot program.
- The therapy is indicated for pediatric and adult patients with severe to profound hearing loss caused by pathogenic variants in the OTOF gene, provided they have preserved outer hair cell function and no prior cochlear implant in the treated ear.
- Otarmeni is delivered as a one-time, bilateral inner-ear (cochlear) surgical delivery using a needle and microcatheter.
- Reported common side effects include middle ear infection, nausea, dizziness and procedural pain.
- The FDA will hold a public meeting on June 4 to discuss program implementation, eligibility criteria and distribution processes for the therapy.
📰 Source Timeline (2)
Follow how coverage of this story developed over time
- Identifies the approved product as Otarmeni (lunsotogene parvec-cwha), the first dual adeno-associated virus vector-based gene therapy.
- Notes FDA characterization of the therapy as "groundbreaking" and that it is the sixth drug and first gene therapy approved under the National Priority Voucher (CNPV) pilot program.
- Clarifies indication: treatment for pediatric and adult patients with severe to profound hearing loss linked to the OTOF gene, with preserved outer hair cell function and no prior cochlear implant in the treated ear.
- Details administration: a one-time, bilateral inner-ear (cochlear) surgical delivery via needle and microcatheter.
- Lists common side effects including middle ear infection, nausea, dizziness, and procedural pain.
- Reports that the FDA will hold a public meeting on June 4 to discuss program implementation, eligibility criteria, and distribution processes for the therapy.